Joana Fernandes, PhD,  —

Joana brings more than 8 years of academic research and experience as well as Scientific writing and editing to her role as a Science and Research writer. She also served as a Postdoctoral Researcher at the Center for Neuroscience and Cell Biology in Coimbra, Portugal, where she also received her PhD in Health Science and Technologies, with a specialty in Molecular and Cellular Biology.

Articles by Joana Fernandes

Sound Pharmaceuticals Gets $1.6 Million to Test SPI-1005 as CF Hearing Loss Therapy

Sound Pharmaceuticals has received a $1.6 million Cystic Fibrosis Foundation Therapeutics (CFFT) grant to test a therapy it has developed to improve hearing loss in cystic fibrosis (CF) patients being treated with tobramycin. Tobramycin is an antibiotic used to treat flare-ups in CF patients’ lung problems that are known as acute pulmonary exacerbations.

Resunab Shows Potential in Treating Lung Inflammation in Preclinical Study

The investigative oral treatment Resunab (JBT-101) shows promise in easing inflammation mediated by immune cells in the lungs of cystic fibrosis (CF) patients, according to results of a preclinical study. Results from a Phase 2 study of the treatment’s safety and efficacy in patients are expected shortly. The preclinical findings will be presented at Research and Development…

CFF Leader Talks About ‘Open Letter’ to President and Concerns with Healthcare Reform

The Cystic Fibrosis Foundation (CFF) joined 72 other organizations, each advocating for patients with chronic, rare and life-threatening diseases, in an open letter to President Donald Trump and leaders in Congress. The letter asks that patients’ needs be taken into consideration as lawmakers revise current healthcare policies. Other groups joining this initiative include the Pulmonary Fibrosis…

Work on Pulmatrix’s PUR1900 for Fungal Infections in CF Patients Bolstered by FDA

The U.S. Food and Drug Administration (FDA) has designated PUR1900 a Qualified Infectious Disease Product (QIDP) as a potential treatment of fungal infections in the lungs of patients with cystic fibrosis(CF), its developer, Pulmatrix, announced. This  designation accelerates the development of new treatments against infectious agents, and protects the exclusivity of PUR1900 for…